{"schema_version":"secwatch.filing_event.v1","accession":"0001575872-22-000269","form_type":"8-K","ticker":"SMNR","cik":"0001913577","company_name":"Semnur Pharmaceuticals, Inc.","filed_at":"2022-04-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.019085+00:00","generated_at":"2026-06-26T08:03:05.450107+00:00","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Denali Capital Acquisition Corp. prices $75M IPO, upsized to $82.5M including over-allotment","bullets":["IPO of 7,500,000 units at $10.00/unit, plus over-allotment of 750,000 units, for total 8,250,000 units.","Gross proceeds $82.5M from IPO and $5.1M from private placement of 510,000 units to sponsor.","Trust account funded with $84.15M; proceeds held until business combination or redemption.","Appoints Huifeng Chang, Jim Mao, Kevin D. Vassily as independent directors; board classified three classes.","Units (DECAU), Class A shares (DECA), and warrants (DECAW) listed on Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001575872-22-000269","json":"https://secwatch.observer/filing/0001575872-22-000269.json","markdown":"https://secwatch.observer/filing/0001575872-22-000269.md","text":"https://secwatch.observer/filing/0001575872-22-000269.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1913577/000157587222000269/0001575872-22-000269-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1913577/000157587222000269/deca-20220406.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T08:03:05.450107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d39721669","claim":"Huifeng Chang was appointed as Director at Semnur Pharmaceuticals, Inc..","evidence_excerpt":"Effective April 6, 2022, in connection with the IPO, Huifeng Chang, Jim Mao and Kevin D. Vassily were appointed directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1913577/000157587222000269/0001575872-22-000269-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c740b19945","claim":"Jim Mao was appointed as Director at Semnur Pharmaceuticals, Inc..","evidence_excerpt":"Effective April 6, 2022, in connection with the IPO, Huifeng Chang, Jim Mao and Kevin D. Vassily were appointed directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1913577/000157587222000269/0001575872-22-000269-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ef0d322a4a","claim":"Kevin D. Vassily was appointed as Director at Semnur Pharmaceuticals, Inc..","evidence_excerpt":"Effective April 6, 2022, in connection with the IPO, Huifeng Chang, Jim Mao and Kevin D. Vassily were appointed directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1913577/000157587222000269/0001575872-22-000269-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}